Catalog No.
DHD15102
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Leukocyte-endothelial cell adhesion molecule 3, Platelet activation dependent granule-external membrane protein, Granule membrane protein 140, GMP-140, CD62P, SELP, GRMP, PADGEM, CD62 antigen-like family member P, LECAM3, P-selectin, GMRP
Concentration
1.68 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16109
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LC1004-002, RO4905417, CAS: 1256258-86-2
Clone ID
Inclacumab
Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers, PMID: 25602360
First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin, PMID: 25714598
Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial, PMID: 27852589
Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects, PMID: 26363899
Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies, PMID: 23522853
Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial, PMID: 23500230
Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial, PMID: 26796402
Advances in clinical cardiology, PMID: 25074280
Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis, PMID: 33510581
Experimental Agents for the Treatment of Atherosclerosis: New Directions, PMID: 33633471
A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease., PMID:37436495
Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics., PMID:36342398
Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials., PMID:35760536
Experimental Agents for the Treatment of Atherosclerosis: New Directions., PMID:33633471
Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis., PMID:33510581
Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial., PMID:27852589
Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial., PMID:26796402
Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects., PMID:26363899
First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin., PMID:25714598
Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers., PMID:25602360
Advances in clinical cardiology., PMID:25074280
Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies., PMID:23522853
Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial., PMID:23500230
For research use only. Not for human or drug use.
